SN
Therapeutic Areas
Fulcrum Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Losmapimod | Facioscapulohumeral Muscular Dystrophy (FSHD) | Phase 3 |
| Pociredir (FTX-6052) | Sickle Cell Disease (SCD) | Phase 1b |
| FTX-6052 | Beta-thalassemia | Discovery |
| FTX-273 | Diamond Blackfan Anemia / Bone Marrow Failure Syndromes | Discovery |
Leadership Team at Fulcrum Therapeutics
BE
Bryan E. Stuart
President and Chief Executive Officer
RJ
Robert J. Gould, Ph.D.
Former President and CEO, Co-founder
JA
Judith A. Dunn, Ph.D.
President of Research and Development
ER
Esther Rajavelu
Chief Financial Officer
CM
Chris Moxham, Ph.D.
Chief Scientific Officer